NovaBay stock: buy or sell?
June 26th, 2019
NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and markets anti-infective products for the eye care market in the United States.
Should I buy NovaBay stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Following a trading plan helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Currently, NovaBay Pharmaceuticals stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is NovaBay Pharmaceuticals stock a buy?
Banks and financial institutions post stock ratings everyday.Unfortunately, we couldn't detect any rating for NBY stock for the last 30 days.
NovaBay stock analysis
NovaBay plunged a chilling -4.55% and closed at $1.68.
Shares of NovaBay plunged a chilling -4.55% and closed at $1.68. Since price and SMA200d lines crossed up on June/10, NBY climbed $1.36 (425.00%).
After boosting an exceptional 13.54% in a week last week, NovaBay Pharmaceuticals closed this week at $1.68 and plunged a bloodcurdling -12.50%.
Since price and SMA40w lines crossed up by mid June, NBY climbed $1.36 (425.00%).
NovaBay stock price history
NovaBay IPO was on January 2nd, 2018 at $3.90 per share1. Since then, NBY stock lost a -56.90%, with a yearly average of -56.90%.
1: Adjusted price after possible price splits or reverse-splits.
NovaBay stock historical price chart
NBY stock reached 52-week highs on Jun/11 at $4.04, and all-time highs 2018-01-02 with a price of 4.2.
NovaBay stock price targetHow much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last 30 days we have not detected any price forecast for NovaBay Pharmaceuticals stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareNovaBay failed experts on March when it published an Earnings per Share (EPS) of $-0.09 when the market consensus was $-0.14.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual sales report draw a spooky slide of -31.39% to $12.51 M USD. Similarly, its income margin (compared to revenues) plunged to -52.33%, that is $-6.55 million.
|2013||$3.48 M||-||$-16.04 M-460.9%||-|
|2014||$1.05 M||-69.71%||$-15.19 M-1441.6%||-5.27%|
|2015||$4.38 M||315.65%||$-18.97 M-433.1%||24.87%|
|2016||$12 M||171.56%||$-13.15 M-110.5%||-30.69%|
|2017||$18 M||53.23%||$-7.40 M-40.6%||-43.71%|
|2018||$13 M||-31.39%||$-6.55 M-52.3%||-11.59%|
Quarterly financial resultsNovaBay Pharmaceuticals reported $3.63 million in sales for 2018-Q4, a 15.37% up compared to previous quarter. Reported quarter earnings marked $-1.27 million with a profit margin of -34.98%. Profit margin boosted a 13.97% compared to previous quarter when profit margin was -48.95%. When comparing revenues to same quarter last year, NovaBay sales marked a chilling correction and plunged a -42.61%. Looking back to recent quarterly results, NovaBay posted 2 negative quarters in a row.
|2017-Q1||$4 M||-||$-4.01 M-108.4%||-|
|2017-Q2||$4 M||11.35%||$-1.74 M-42.2%||-56.61%|
|2017-Q3||$4 M||-0.70%||$-2.45 M-59.8%||40.63%|
|2017-Q4||$6 M||54.39%||$0.79 M12.6%||-132.41%|
|2018-Q1||$3 M||-53.34%||$-2.15 M-73.0%||-371.12%|
|2018-Q2||$3 M||-5.19%||$-1.59 M-56.9%||-26.09%|
|2018-Q3||$3 M||12.46%||$-1.54 M-48.9%||-3.21%|
|2018-Q4||$4 M||15.37%||$-1.27 M-35.0%||-17.56%|
NovaBay ownershipWhen you are planning to invest in shares of a company, it's worth to check its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For NovaBay Pharmaceuticals, 25.87% of all outstanding shares are owned by its staff.
In case of NovaBay stock, 4.11% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for NBY stock account 0.00%, no big difference from last month.
For a better understanding, the following table shows ownership data compared to other related stocks:
|Market cap||$31.9 M||$377.3 B||$19.2 M||$436.3 M||$94.6 M|
|Total shares||19.0 M||2,660.0 M||76.7 M||80.9 M||12.0 M|
|Float shares||7.1 M||2,650.0 M||54.5 M||49.7 M||11.7 M|
|- Institutional holdings (%)||4.1%||69.2%||5.0%||30.2%||14.5%|
|- Insider holdings (%)||25.9%||0.1%||28.1%||33.0%||2.0%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Wednesday, June 26th, 2019|
|Day range||$1.66 - $1.76|
|Average true range||$0.65|
|50d mov avg||$0.99|
|100d mov avg||$1.19|
|200d mov avg||$1.27|
NovaBay performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We chose , NanoViricides, SIGA Technologies, Sonoma Pharmaceuticals and Tetraphase Pharmaceuticals as the bechmarking frame for NovaBay Pharmaceuticals stock.